Precigen, Inc. PGEN
Regular-session close
After hours · Nov 20, 6:21 PM ET
- YTD
- +0.72%
- 1 year
- +7.95%
5D -0.22 (-4.97%)
- Market cap
- 1.51B
- Revenue (ttm)
- 156.94M
- Profit margin
- 15.55%
- EPS (ttm)
- 0.11
- Shares out
- 358.55M
- P/E ratio
- 38.27
- Forward P/E
- -19.14
- YTD return
- +0.72%
- 1-year return
- +7.95%
- 50-day average
- 6.53
- Volume
- 6.07M
- Avg volume
- 5.65M
- Open
- 4.16
- Previous close
- 4.16
- Day's range
- 4.07 – 4.36
- 52-week range
- 3.10 – 8.56
- Beta
- 0.98
- Analysts
- Buy
- Price target
- 13.67 (+224.6%)
- Earnings date
- Mar 24, 2027
Key statistics
- 200-day average
- 5.27
- Enterprise value
- 1.54B
- Price / sales
- 9.62
- Price / book
- 17.99
- Revenue growth
- 2437.60%
- Free cash flow
- -87.13M
- Total cash
- 46.07M
- Total debt
- 98.61M
- Return on equity
- 38.84%
- Short % of float
- 22.95%
Fundamental scorecard
9 of 25 checks passed on PGEN’s reported financials
9of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 11.00
- Target (mean)
- 13.67
- Target (high)
- 18.00
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 24, 2027
Expected Mar 24, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 24, 2027 | Dec 30, 2026 | 0.11 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.06 | 0.08 | +0.02 | +33.33% |
| Aug 4, 2026 | Jun 30, 2026 | -0.01207 | 0.05 | +0.06 | +514.25% |
| May 13, 2026 | Mar 31, 2026 | -0.03 | -0.02 | +0.01 | +33.33% |
| Mar 25, 2026 | Dec 31, 2025 | -0.10 | -0.0664 | +0.03 | +33.60% |
| Nov 13, 2025 | Sep 30, 2025 | -0.08 | -1.06 | -0.98 | -1,225.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2026 | B. Riley Securities | reit | Buy | Buy |
| Nov 5, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Sep 25, 2026 | B. Riley Securities | init | — | Buy |
| Aug 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 3, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 28, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Precigen, Inc.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- precigen.com
News
Precigen: Upgrading To Buy As Competitive Fears Over VOCERYQ Look Overblown B. Riley Securities Reiterates Buy on Precigen, Lowers Price Target to $11
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12
Precigen Q3 2026 Earnings Call Transcript Precigen Q3 EPS $0.08 Beats $0.07 Estimate, Sales $74.148M Beat $71.558M Estimate
Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Friday's After-Market Session
Your note
Sign in to keep a note on PGEN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALVAREZ CESAR LICINIO | Director | Conversion of Exercise of derivative security | Mar 12, 2026 | 782,909 |
| FRANK STEVEN R | Director | Conversion of Exercise of derivative security | Mar 12, 2026 | 1,226,390 |
| GUPTA VINITA D | Director | Conversion of Exercise of derivative security | Mar 12, 2026 | 666,027 |
| HASSAN FRED | Director | Conversion of Exercise of derivative security | Mar 12, 2026 | 1,243,240 |
| KIRK RANDAL JOE | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 29, 2026 | 0 |
| LEHR DONALD P | Officer | Conversion of Exercise of derivative security | Aug 20, 2026 | 758,181 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Patient Capital Management, LLC | 5.01% | 17,950,104 | 75.57M | Sep 29, 2026 |
| Blackrock Inc. | 4.82% | 17,280,537 | 72.75M | Sep 29, 2026 |
| State Street Corporation | 2.99% | 10,719,117 | 45.13M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 2.23% | 8,011,028 | 33.73M | Sep 29, 2026 |
| Tang Capital Management, LLC | 1.79% | 6,417,500 | 27.02M | Sep 29, 2026 |
| Geode Capital Management, LLC | 1.42% | 5,087,896 | 21.42M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trust for Advised Portfolios-Patient Opportunity Trust | 3.35% | 12,000,000 | 50.52M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.59% | 5,690,796 | 23.96M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.58% | 5,673,921 | 23.89M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.39% | 4,995,494 | 21.03M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.59% | 2,113,914 | 8.90M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.56% | 2,020,238 | 8.51M | Jun 29, 2026 |
